{"filing":{"accession_number":"0001104659-26-091629","cik":"0001557746","ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"acrs-20260806x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806x8k.htm"},"events":[{"id":25405,"run_id":23058,"accession_number":"0001104659-26-091629","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Aclaris Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing includes condensed consolidated statements of operations showing net loss of $21.5 million for Q2 2026 and $41.3 million for the six-month period, along with balance sheet and cash flow data. The press release (Exhibit 99.1) announces these quarterly and year-to-date financial results, which is the hallmark of an earnings_release event under Item 2.02.","company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26228,"accession_number":"0001104659-26-091629","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Aclaris Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing includes condensed consolidated statements of operations showing net loss of $21.5 million for Q2 2026 and $41.3 million for the six-month period, along with balance sheet and cash flow data. The press release (Exhibit 99.1) announces these quarterly and year-to-date financial results, which is the hallmark of an earnings_release event under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:20.276307+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26228,"accession_number":"0001104659-26-091629","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Aclaris Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing includes condensed consolidated statements of operations showing net loss of $21.5 million for Q2 2026 and $41.3 million for the six-month period, along with balance sheet and cash flow data. The press release (Exhibit 99.1) announces these quarterly and year-to-date financial results, which is the hallmark of an earnings_release event under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:20.276307+00:00","company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","filing_date":"2026-08-06"}]}